Head to head
Survodutide against Tirzepatide
Two ways of adding a second receptor to GLP-1, glucagon in one case and GIP in the other. One is approved and one is investigational, and the comparison that would separate the two mechanisms in the same people has not been run.
Column A
SurvodutideSurvodutide (GLP-1 / glucagon dual agonist)
An investigational once-weekly GLP-1 and glucagon receptor dual agonist studied for obesity and metabolic liver disease.
Column B
TirzepatideTirzepatide (dual GIP/GLP-1 receptor agonist)
A first-in-class dual GIP and GLP-1 receptor agonist with superior weight loss and glycemic control versus GLP-1 mono-agonists.
Side by side, on the facts we can check
| Attribute | Survodutide | Tirzepatide |
|---|---|---|
| Category | Metabolic | Metabolic |
| FDA status | Investigational, not FDA-approved | FDA-approved (Mounjaro for T2D and, from August 2026, to reduce major cardiovascular events in T2D; Zepbound for weight management and sleep apnea) |
| Half-life | ~6 days | ~5 days |
| Molecular weight | ~4,900 Da | 4,813.5 Da |
| Mechanism | Agonizes both GLP-1 and glucagon receptors, combining appetite suppression and improved glucose handling with increased energy expenditure and hepatic fat reduction. | Simultaneously activates GIP and GLP-1 receptors, enhancing glucose-dependent insulin secretion, reducing glucagon, delaying gastric emptying, and reducing appetite. The GIP component is thought to add complementary metabolic effects. |
| Human studies cited | 3 | 4 |
| Legal status, US | Investigational, not approved | FDA-approved, prescription only |
Frequently asked questions
What is the difference between Survodutide and Tirzepatide?
Survodutide: An investigational once-weekly GLP-1 and glucagon receptor dual agonist studied for obesity and metabolic liver disease. Tirzepatide: A first-in-class dual GIP and GLP-1 receptor agonist with superior weight loss and glycemic control versus GLP-1 mono-agonists.
Which has stronger research evidence, Survodutide or Tirzepatide?
This database does not grade compounds. It counts what was run in people: 3 of the 3 studies cited on the Survodutide profile were human work, against 4 of 4 for Tirzepatide. Those counts are of our own citation lists and understate any larger literature, and neither is a recommendation.
Are Survodutide and Tirzepatide FDA-approved?
Survodutide: Investigational, not FDA-approved. Tirzepatide: FDA-approved (Mounjaro for T2D and, from August 2026, to reduce major cardiovascular events in T2D; Zepbound for weight management and sleep apnea).
Related posts
Blog articles that cover Survodutide or Tirzepatide, newest first.
- Dispatch / Sep 12, 2026 / 8 minDispatch 001: Five Retatrutide Phase 3 Trials Have Finished And None Has Posted Results
- Metabolic / Sep 8, 2026 / 8 minTesofensine Is Not a Peptide: What It Is, the Trials, and the Heart-Rate Issue
- Metabolic / Sep 8, 2026 / 10 minOral GLP-1s in 2026: Wegovy Pill vs Foundayo (Orforglipron) vs Rybelsus, and What Is Coming
- Metabolic / Sep 8, 2026 / 9 minMariTide (Maridebart Cafraglutide): The Once-Monthly GLP-1 Agonist and GIP Blocker, Explained
Reviewed Sep 2026. This page sets two published records side by side. It is educational, it is not medical advice, and it contains no dosing protocols or recommendations for personal use.